Introduction and Objective: The 2019 ADA Pharmacotherapy Guidelines for type 2 diabetes (T2D) recommended patient-centric prescribing based on clinical conditions such as prevalent ASCVD, high risk for CVD, heart failure (HF), CKD, and obesity. Prior analyses showed 40% guideline adoption. Methods: This multi-year cross-sectional study examined prescribing practice for patients with T2D from 2018 to 2024 using Veradigm Network Electronic Health Records (EHR). Patients active in the EHR for 2 consecutive years, with a T2D diagnosis, HbA1c, and BMI in the study year were selected. Clinical groups were defined via baseline year diagnoses; patients could meet criteria for 1 clinical group. Unadjusted odds ratios were used to compare treatment in clinical groups with no groups. Results: Guideline adherence increased from 2018 (15.8%) to 2024 (38.2%) among all patients. However, odds of guideline adherence vs. no group for the overall clinical group declined from 1.20 (2018) to 1.13 (2024), while it remained consistently higher for obesity, and improved the most HF group from 0.60 in 2018 to 1.35 in 2024 (Figure). Odds ratio of adherence ranged from 1.10 (ASCVD) to 1.55 (obesity) in 2024. Data showed untreated T2D patients increased from 21.1% in 2018 to 35.7% in 2024. Conclusion: Although guideline adherence improved between 2018 to 2024, there’s still much room for improvement in treating the untreated and targeting the recommended patients per guidelines. Disclosure J.P. Bae: Employee; Current; Eli Lilly and Company. T. Ryan: Consultant; Current; Eli Lilly and Company. K. Terrell: Employee; Current; Eli Lilly and Company. C. Adams: Consultant; Current; Eli Lilly and Company. J. Peleshok: Employee; Current; Eli Lilly and Company. B. Limone: Consultant; Current; Eli Lilly and Company. F. Tangi: Employee; Current; Eli Lilly and Company. E. Marchlewicz: Consultant; Current; Eli Lilly and Company. Funding This study was funded by Eli Lilly and Company.
BAE et al. (Fri,) studied this question.